James G. Jakowatz
Professor, Surgery
School of Medicine
School of Medicine
Director, Melanoma Center, Surgery
School of Medicine
School of Medicine
M.D., University of Kansas, 1978
M.S., University of Illinois, 1982
B.A., University of Kansas, 1975, Biology
M.S., University of Illinois, 1982
B.A., University of Kansas, 1975, Biology
University of California, Irvine
Bldg 23 - Rt 81
101 The City Drive
Mail Code: 5376
Orange, CA 92668
Bldg 23 - Rt 81
101 The City Drive
Mail Code: 5376
Orange, CA 92668
Research Interests
Oncologic Surgery, Melanoma, Melanoma Research, Soft Tissue Sarcoma, Breast Cancer
Academic Distinctions
Two Golden Apple Awards for medical student teaching
One Silver Apple Award for medical student teaching
The John E. Connolloy Award for resident teaching
The Golden Scalpel Award for medical student teaching
One Silver Apple Award for medical student teaching
The John E. Connolloy Award for resident teaching
The Golden Scalpel Award for medical student teaching
Research Abstract
Currently we are trying to use spectral imaging on pigmented lesions oon the skin to be able to determine if a biopsy is necessary or not. this essentially is advanced mole mapping, trying to see if spectral images are a reliable method of evaluation that can not only avoid multiple biopsies, but also diagnose early melanomas.
Publications
1. Jakowatz, JG, Cullen ML, Anderson K, Economou SG, Southwick HW. The stability of estrogen and progesterone receptors as an operative advantage. Breast 7:2-5, 1981.
2. Deziel DJ, Jakowatz JG, Stibolt TB, et al. The frequency response of the canine choledochoduodenal junction. Curr Surg 41:94-97, 1984.
3. Jakowatz JG, Porudominsky D, Braly P, Riihimaki DU, Kokal WA, Kemeny MM, Terz JJ, Beatty JD. Complications of pelvic exenteration. Arch Surg 120:1261-1265, 1985.
4. Jakowatz JG, Beatty BG, Vlahos WG, Porudominsky D, Williams LE, Paxton RJ, Shively JE, Beatty JD. A high specific activity 111In-labeled anti-carcinoembryobic antigen monoclonal antibody. II. Biodistribution and imaging in nude mice bearing human colon cancer xenografts. Cancer Research 45:5700-5706, 1985.
5. Paxton RJ, Jakowatz JG, Beatty JD, Beatty BG, Vlahos WG, Williams LE, Clark BR, Shively JE. Preparation of a high specific activity 111In-labeled anti-CEA monoclonal antibody. I. An improved method for synthesis of DTPA-conjugates. Cancer Research 45:5694-5699, 1985.
6. Philben VJ, Jakowatz JG, Beatty BG, Vlahos WG, Paxton RJ, Williams LE, Shively JE, Beatty JD. 111In-labeled anti-CEA monoclonal antibody. The effect of tumor size and CEA content. Cancer 57:571-576, 1986.
7. Wile AG, Kar R, Cohen RA, Jakowatz JG, Opfell RW. The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 59:695-700, 1987.
8. Sarfeh IJ, Rypins EB, Jakowatz JG, Juler GL. A Prospective, randomized clinical investigation of cholecystoenterostomy. American Journal of Surgery 155:411-414, 1988.
9. Tenzer JA, Rypins RD, Jakowatz JG. Malignant cystosarcoma phylloides metastatic to the maxilla. J Oral & Maxillofac Surg 46:80-82, 1988.
10. Jakowatz JG, Gan K, Ulich TR, Wile AG. Murine monoclonal antibodies to human pancreatic cancer: Specificity and sensitivity. Oncology 47:149-154 March-April 1990.
11. Jakowatz JG, Ginn GE*, Snyder L*, Diffenbach K*, Wile AG. Increased cisplatin tissue levels with prolonged arterial infusion in the rat. Cancer 67:11, 2828-2832, 1990.Cancer,
*Surgical resident under Dr. Jakowatz's direction.
12. Carson WE*, Jakowatz JG, Yamamoto RS, Fitzgerald T, Gupta S, Vayuvegula B, Lucci JA, Beckman MT, Dulkanchainun SB, Granger GA, and Jeffes EWB. Rat mitogen-stimulated lymphokine activated (MAK) T killer cells: Production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats. Journal of Immunotherapy 10:131-140, 1990.
*Surgical resident under Dr. Jakowatz's direction
13. Liu SK*, Jakowatz JG, Pollack RB*, Yamamoto RS, Dett CA, Lopez F, Camacho C, Carson WE*, Sentovich, S*, Jacques D, and Granger GA. Effects of Intracarotid and Intravenous Infusions of Human TNF and Lymphotoxin on Established Intracerebral Rat Gliomas. Lymphokine & Cytokine Res. 10:3, 189-194, 1991.
*Surgical resident under Dr Jakowatz's direction.
14. Gordon IL, Rypins EB, Wuerker RB, Jakowatz JG. Cytologic detection of colorectal cancer after administration of oral lavage solution. Cancer 68:106-110, 1991.
15. Yamamoto RS, Coss J, Vayuvegula B, Gupta S, Beamer Y, Jacques S, Jeffes EWB, Carson WE*, Jakowatz JG, Granger GA. Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent gliomablastoma. J of Immunologic Methods 137:225-235, 1991.
*Surgical resident under Dr. Jakowatz's direction.
16. Elias AN, Jakowatz JG, Pandian MR. Parathyroid hormone related protein (PTHrP) in patients with malignant melanoma. Archives of Dermatology, 128:278-279, October 1991.
17. Waki EY, Crumley RL, Jakowatz JG. Effects of pharmacologic agents on human keloids implanted in athymic mice: A pilot study. Archives of Otolaryngology--Head and Neck Surgery, October 1991, 117(10):1177-81.
18. Sarfeh IJ and Jakowatz JG. Surgical treatment of enteric "Bud" fistulae in contaminated wounds. Arch Surg 127:1027-1031, September 1992.
19. Goodman M and Jakowatz J. Skin Cancer Prevention, Medical Update, Skin Inc., March 1991.
20. Hourani LL, Jakowatz J, Goodman M, Mueller G, Brodie G, Jaffery A. Concordance of Hospital Cancer Registry- and Physician-Collected Data for Patients with Melanoma. JNCI 84(22):1749-1750, November, 1992.
21. Wuerker RB, Gordon IL, Jakowatz JG: Characteristics of Cancer Cells in Gastrointestinal Lavage Specimens. Acta Cytol 37:379-384, May-June 1993.
22. Mitchell MS, Jakowatz JG, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased Effectiveness of Interferon-alpha 2b Following Active Specific Immunotherapy for Melanoma. J Clin Oncol 12(2):402-411, 1994.
23. Jakowatz JG, Meyskens FL. Evaluation and treatment of the patient with early melanoma. Comprehensive Therapy 21(1):46-50, 1995.
24. Grant SW*, Kyshtoobayeva AS, Kurosaki T, Jakowatz JG, Fruehauf JP. Mutant p53 Correlates with Reduced Expression of Thrombospondin-1, Increased Angiogenesis, and Metastatic Progression Melanoma. Cancer Detection and Prevention 22 (3):185-194, 1998.
*Surgical resident under Dr. Jakowatz’s direction.
25. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Jakowatz JG, et al. Adjuvant Immunotherapy of Resected, Intermediate-Thickness Node-Negative Melanoma with an Allogeneic Tumor Vaccine. I. Overall results of a Ramdomized Trial of the Southwest Oncology Group. Journal of Clinical Oncology, Vol 20, No 8, pp 2058-2066, 2002.
26. Podnos YD, Jimenez JC, Zainabadi K, Jakowatz JG, Barr RJ. Minimal Deviation Melanoma. Cancer Treatment Reviews 2002 28: 219-221
27. Bagwell BD, Valentino DJ, Jeffes EW, Dieffenbach K,Dulkanchainum SB, Yamamoto RS, Granger GA, Jakowatz JG, Carson WE. Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma. Cancer Immunology Immunotherapy (2003) 52: 10-16
28. Cole MD, Jakowatz JG, Evans GR. Evaluation of Nodal Patterns for Melanoma of the Ear. Plastic and Reconstructive Surgery 112: 50, 2003
29. Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz JG, Reed RJ. Ki-67 and p53 Expression in Minimal Deviation Melanomas as Compared with Other Nevomelanocytic Lesions. Modern Pathology Vol 16, No. 6,p. 525, 2003
30. Wong SF, Jakowatz J, & Taheri R, Potential Drug Interaction between Interferon and Gemfibrozil in a Malignant Melanoma Patient. Clinical Therapeutics 2005; 27:1942-1948
31. Malcolm S. Mitchell...James G. Jakowatz, et al. Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma. Journal of Clinical Oncology, Vol 25, No 15 May 20), 2007: pp. 2078-2085
IN PRESS
1. Powell LL, Krug RJ, Carpenter S, Williams RA, Wilson SE, Jakowatz J, Butler J. Successful Surgical Treatment of Mucinous Cystadenocarcinoma of the Pancreas Arising from
a Villous Adenoma of the Ampulla. Submitted to Surgery.
BOOKS
1. Jakowatz, James, Contributing Author: Surgery Board Review Guide, Samuel Eric Wilson, Consulting Editor, University of California, Irvine - Bayer Pharmaceutical Division August, 1996. Revised 2003
2. Jakowatz JG, contributing author: Placement of Indwelling Venous Access Systems in Vascular Access Surgery, 3rd Edition & 4th editions (Mosby Year Book, Inc., Publishers). 1996, 2000
BOOK CHAPTERS
1. Granger GA, Gatanaga T, Yamamoto YA, Grosen E, Cappuccini F, Jeffes E, Jakowatz J, DiSaia P. Studies on the Action of Human TNF/LT and Their Blocking Factors in Cancer Patients in: New Frontiers in the Therapy of Malignancies: From Biological Approaches to Clinical Trials; Serono Symposia Review No. 25:30-39, 1991, Rome, Italy.
2. Granger GA, Yamamoto R, Gatanaga T, Cappuccini F, Jeffes EWB, Jakowatz JG. Lymphotoxin, Macrophage Toxins, Tumor Necrosis Factor and Cachectin in Tumor Necrosis Factor: Structure-Function Relationship and clinical Application. Basel, Karger, 1992:25-33. ***[International Conference on Cytokines and Tumor Necrosis Factor, Japan, 1991.]***
3. Jakowatz JG, et al: Placement of Indwelling Venous Access Systems in Vascular Access Surgery, 3rd Edition (Mosby Year Book, Inc., Publishers). 1996.
4. Jakowatz JG, et al: Indications, Devices and Techniques for Chronic Venous Access Devices Vascular Access: Principles and Practice, 4th Edition. (Mosby Year Book, Inc., Publishers).2002.
5. Jakowatz JG, Contributing Author: Cancer Prevention and Early Detection in Women, Manetta A. – Elsvier Mosby, October 2003.
6. Jakowatz JG, Contributing Author: Proecdures in Reconstructive Plastic Surgery, Elsvier, November 2008
ABSTRACTS
1. Jakowatz JG, Gan K, Ulich TR, Wile AG. Monoclonal antibodies and human pancreatic cancer. Proc Amer Soc Clin Oncology, Vol 6, abstract #925 p 235, May, 1987.
2. Jakowatz JG, Gan K, Ulich TR, Wile AG. Preneoplastic antigenic expression in non-neoplastic pancreatic tissue of pancreatic carcinoma and pancreatitis. Proceedings of the International Academy of Pathology Annual Meeting, March 1987, Boston, Massachusetts
3. Carson WE*, Jakowatz JG, Diffenbach, K*,et al. Intra-arterial TNF-alpha as treatment for regionally confined experimental extremity tumors in rats. 2nd International Conference on Tumor Necrosis Factor and Related Cytokines, No. WA 007, p 5, January 1989.
*Surgical residents under Dr. Jakowatz's direction.
4. Yamamoto RS, Beamer Y, Jacques D, Jeffes EWB, Jakowatz JG, Coss J, Granger, GA. Studies on longterm cultured human LAK cells from normal donors and patients with recurrent glioma. Growth characteristics, cytolytic activity and phenotype. FASEB Journal 3(3):827, abstract no. 3490, February 1989.
5. Jakowatz JG, Snyder, L*, Ginn, G*, et al. Effect of route and schedule of cisplatin administration. Proc Amer Soc Clin Oncology, Vol 8, p 66, March 1989.
*Surgical resident under Dr. Jakowatz's direction.
6. Carson WE*, Jakowatz JG, Diffenbach K*, Lucci J, Jeffes EWB, Yamamoto R, and Granger G. Intra-arterial TNF-alpha as treatment for regionally confined experimental extremity tumors in rats. Program and Abstracts of the 1989 Society for Biological Therapy Annual Meeting, abstract # 69, p 20, Boston, MA, November, 1989.
*Surgical residents under Dr. Jakowatz's direction.
7. Jeffes EWB, Yamamoto R, Beamer Y, Silberman R, Jacques D, Jakowatz JG, Gupta S, Vayuvegula B, and Granger G. Mitogen stimulated, IL-2 activated (MAK) lymphocyte therapy of recurrent high grade glioma patients. Program and Abstracts of the 1989 Society for Biological Therapy Annual Meeting, abstract # 68, p 20, Boston, MA, November, 1989.
8. Jakowatz JG, Carson, WE*, Sentovich S*, Dulkanchainum S, and Granger GA. Intra-arterial TNF for regionally confined extremity tumors in rats. Proc Amer Soc Clin Oncology, Vol 9, abstract # 321, p 83, May 1990.
*Surgical residents under Dr. Jakowatz's direction.
9. Liu S*, Jakowatz JG, Ceraldi C*, Sentovich S*, and Granger GA. Treatment of experimental brain gliomas with intracarotid tumor necrosis factor-alpha infusion. Proc Amer Assn Cancer Res, Vol 31, abstract # 1757, p 296, May 1990.
*Surgical residents under Dr. Jakowatz's direction.
10. Liu SK*, Jakowatz JG, Granger GA, Dett CA, Lopez F, Camacho C, Carson WE, and Sentovich S*. Immunotherapy of Brain Gliomas II. Efficacy of Intracarotid TNF and Intracarotid Lymphotoxin Compared in a Syngeneic Rat Model. Accepted for publication, Proceedings of the 3rd International Conference on Tumor Necrosis Factor and Related Cytokines, Sept., 1990.
11. Jeffes E, Yamamoto R, Beamer Y, Silberman R, Jacques D, Jakowatz J. Immunotherapy of human glioma II: Mitogen Stimulated IL-2 activated killer (MAK) lymphocyte therapy of recurrent high grade gliomas. Accepted for publication, Congress of Neurological Surgeons Annual Meeting, October 1990.
12. Sentovich S*, Jakowatz J, Ceraldi C*, Carson W*, Dett C, Granger G, and Liu S. Immunotherapy of brain cancer gliomas I: Efficacy of intracarotid TNF in Wistar rats. Submitted for publication, Congress of Neurological Surgeons Annual Meeting, October, 1990.
13. White JI, Gardner VO, Thalgott JS, Jakowatz JG, Palafox B, Hiroyuki T. Anterior Lumbar Fusion Using Allograft Femoral Shaft Bone: Preliminary Results. Accepted, Fifth International Conference on Lumbar Fusion and Stabilization, abstract #081, July 1991.
14. Sarfeh IJ and Jakowatz JG. Surgical Treatment of Enteric "Bud" Fistulae in Contaminated Wounds: A Riskless Extraperitoneal Method Using Split Thickness Skin Grafts. Accepted So. California Chapter of the American College of Surgeons, September 1991.
15. Meyskens FL Jr., Yamanishi DT, Jakowatz J, Goodman M. Abnormalities of Protein Kinase C (PKC)-B and Retinoic Acid Receptor (RAR)-B Expression During Human Melanocyte Progression to Melanoma. Accepted for presentation at the Third International Conference on Melanoma to be held in Venice, Italy 3-31-93.
16. Gordon IL, Jakowatz JG, Wuerker RB, and Willis, L. Detection of Colorectal Cancer Cells in Lavage Induced Stool. Submitted to the Society for Surgery of the Alimentary Tract New Orleans, May 1994.
17. Gordon IL, Ruth GD, Abai Y, Jakowatz JG, and Willis L. Increased Exfoliation of Gut Mucosal Cells Induced by Chenodeoxycholic Acid. Submitted to the Society for Surgery of the Alimentary Tract, New Orleans, May 1994.
18. Lugo S, Schechter A, Butler J, Jakowatz JG, and Gordon I. Automatic Minimally Invasive Morcellation System Allows Adequate Histologic Interpretation of Excised Tissue. The Southwestern Surgical Congress, April, 1994.
19. Regional Differences in the use of Sentinel Lymph Node Biopsy for Melanoma: A Potential Quality Measure. Karen Lane, MD, Ashley Kempf, BS, Cheryl Magno, MPH, John Lane, MD, John Butler, MD, David Hsiang, MD, Shelly Greenfield, MD, James Jakowatz, MD. Am Surg. 2008 Oct;74(10):981-4.
2. Deziel DJ, Jakowatz JG, Stibolt TB, et al. The frequency response of the canine choledochoduodenal junction. Curr Surg 41:94-97, 1984.
3. Jakowatz JG, Porudominsky D, Braly P, Riihimaki DU, Kokal WA, Kemeny MM, Terz JJ, Beatty JD. Complications of pelvic exenteration. Arch Surg 120:1261-1265, 1985.
4. Jakowatz JG, Beatty BG, Vlahos WG, Porudominsky D, Williams LE, Paxton RJ, Shively JE, Beatty JD. A high specific activity 111In-labeled anti-carcinoembryobic antigen monoclonal antibody. II. Biodistribution and imaging in nude mice bearing human colon cancer xenografts. Cancer Research 45:5700-5706, 1985.
5. Paxton RJ, Jakowatz JG, Beatty JD, Beatty BG, Vlahos WG, Williams LE, Clark BR, Shively JE. Preparation of a high specific activity 111In-labeled anti-CEA monoclonal antibody. I. An improved method for synthesis of DTPA-conjugates. Cancer Research 45:5694-5699, 1985.
6. Philben VJ, Jakowatz JG, Beatty BG, Vlahos WG, Paxton RJ, Williams LE, Shively JE, Beatty JD. 111In-labeled anti-CEA monoclonal antibody. The effect of tumor size and CEA content. Cancer 57:571-576, 1986.
7. Wile AG, Kar R, Cohen RA, Jakowatz JG, Opfell RW. The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 59:695-700, 1987.
8. Sarfeh IJ, Rypins EB, Jakowatz JG, Juler GL. A Prospective, randomized clinical investigation of cholecystoenterostomy. American Journal of Surgery 155:411-414, 1988.
9. Tenzer JA, Rypins RD, Jakowatz JG. Malignant cystosarcoma phylloides metastatic to the maxilla. J Oral & Maxillofac Surg 46:80-82, 1988.
10. Jakowatz JG, Gan K, Ulich TR, Wile AG. Murine monoclonal antibodies to human pancreatic cancer: Specificity and sensitivity. Oncology 47:149-154 March-April 1990.
11. Jakowatz JG, Ginn GE*, Snyder L*, Diffenbach K*, Wile AG. Increased cisplatin tissue levels with prolonged arterial infusion in the rat. Cancer 67:11, 2828-2832, 1990.Cancer,
*Surgical resident under Dr. Jakowatz's direction.
12. Carson WE*, Jakowatz JG, Yamamoto RS, Fitzgerald T, Gupta S, Vayuvegula B, Lucci JA, Beckman MT, Dulkanchainun SB, Granger GA, and Jeffes EWB. Rat mitogen-stimulated lymphokine activated (MAK) T killer cells: Production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats. Journal of Immunotherapy 10:131-140, 1990.
*Surgical resident under Dr. Jakowatz's direction
13. Liu SK*, Jakowatz JG, Pollack RB*, Yamamoto RS, Dett CA, Lopez F, Camacho C, Carson WE*, Sentovich, S*, Jacques D, and Granger GA. Effects of Intracarotid and Intravenous Infusions of Human TNF and Lymphotoxin on Established Intracerebral Rat Gliomas. Lymphokine & Cytokine Res. 10:3, 189-194, 1991.
*Surgical resident under Dr Jakowatz's direction.
14. Gordon IL, Rypins EB, Wuerker RB, Jakowatz JG. Cytologic detection of colorectal cancer after administration of oral lavage solution. Cancer 68:106-110, 1991.
15. Yamamoto RS, Coss J, Vayuvegula B, Gupta S, Beamer Y, Jacques S, Jeffes EWB, Carson WE*, Jakowatz JG, Granger GA. Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent gliomablastoma. J of Immunologic Methods 137:225-235, 1991.
*Surgical resident under Dr. Jakowatz's direction.
16. Elias AN, Jakowatz JG, Pandian MR. Parathyroid hormone related protein (PTHrP) in patients with malignant melanoma. Archives of Dermatology, 128:278-279, October 1991.
17. Waki EY, Crumley RL, Jakowatz JG. Effects of pharmacologic agents on human keloids implanted in athymic mice: A pilot study. Archives of Otolaryngology--Head and Neck Surgery, October 1991, 117(10):1177-81.
18. Sarfeh IJ and Jakowatz JG. Surgical treatment of enteric "Bud" fistulae in contaminated wounds. Arch Surg 127:1027-1031, September 1992.
19. Goodman M and Jakowatz J. Skin Cancer Prevention, Medical Update, Skin Inc., March 1991.
20. Hourani LL, Jakowatz J, Goodman M, Mueller G, Brodie G, Jaffery A. Concordance of Hospital Cancer Registry- and Physician-Collected Data for Patients with Melanoma. JNCI 84(22):1749-1750, November, 1992.
21. Wuerker RB, Gordon IL, Jakowatz JG: Characteristics of Cancer Cells in Gastrointestinal Lavage Specimens. Acta Cytol 37:379-384, May-June 1993.
22. Mitchell MS, Jakowatz JG, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased Effectiveness of Interferon-alpha 2b Following Active Specific Immunotherapy for Melanoma. J Clin Oncol 12(2):402-411, 1994.
23. Jakowatz JG, Meyskens FL. Evaluation and treatment of the patient with early melanoma. Comprehensive Therapy 21(1):46-50, 1995.
24. Grant SW*, Kyshtoobayeva AS, Kurosaki T, Jakowatz JG, Fruehauf JP. Mutant p53 Correlates with Reduced Expression of Thrombospondin-1, Increased Angiogenesis, and Metastatic Progression Melanoma. Cancer Detection and Prevention 22 (3):185-194, 1998.
*Surgical resident under Dr. Jakowatz’s direction.
25. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Jakowatz JG, et al. Adjuvant Immunotherapy of Resected, Intermediate-Thickness Node-Negative Melanoma with an Allogeneic Tumor Vaccine. I. Overall results of a Ramdomized Trial of the Southwest Oncology Group. Journal of Clinical Oncology, Vol 20, No 8, pp 2058-2066, 2002.
26. Podnos YD, Jimenez JC, Zainabadi K, Jakowatz JG, Barr RJ. Minimal Deviation Melanoma. Cancer Treatment Reviews 2002 28: 219-221
27. Bagwell BD, Valentino DJ, Jeffes EW, Dieffenbach K,Dulkanchainum SB, Yamamoto RS, Granger GA, Jakowatz JG, Carson WE. Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma. Cancer Immunology Immunotherapy (2003) 52: 10-16
28. Cole MD, Jakowatz JG, Evans GR. Evaluation of Nodal Patterns for Melanoma of the Ear. Plastic and Reconstructive Surgery 112: 50, 2003
29. Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz JG, Reed RJ. Ki-67 and p53 Expression in Minimal Deviation Melanomas as Compared with Other Nevomelanocytic Lesions. Modern Pathology Vol 16, No. 6,p. 525, 2003
30. Wong SF, Jakowatz J, & Taheri R, Potential Drug Interaction between Interferon and Gemfibrozil in a Malignant Melanoma Patient. Clinical Therapeutics 2005; 27:1942-1948
31. Malcolm S. Mitchell...James G. Jakowatz, et al. Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma. Journal of Clinical Oncology, Vol 25, No 15 May 20), 2007: pp. 2078-2085
IN PRESS
1. Powell LL, Krug RJ, Carpenter S, Williams RA, Wilson SE, Jakowatz J, Butler J. Successful Surgical Treatment of Mucinous Cystadenocarcinoma of the Pancreas Arising from
a Villous Adenoma of the Ampulla. Submitted to Surgery.
BOOKS
1. Jakowatz, James, Contributing Author: Surgery Board Review Guide, Samuel Eric Wilson, Consulting Editor, University of California, Irvine - Bayer Pharmaceutical Division August, 1996. Revised 2003
2. Jakowatz JG, contributing author: Placement of Indwelling Venous Access Systems in Vascular Access Surgery, 3rd Edition & 4th editions (Mosby Year Book, Inc., Publishers). 1996, 2000
BOOK CHAPTERS
1. Granger GA, Gatanaga T, Yamamoto YA, Grosen E, Cappuccini F, Jeffes E, Jakowatz J, DiSaia P. Studies on the Action of Human TNF/LT and Their Blocking Factors in Cancer Patients in: New Frontiers in the Therapy of Malignancies: From Biological Approaches to Clinical Trials; Serono Symposia Review No. 25:30-39, 1991, Rome, Italy.
2. Granger GA, Yamamoto R, Gatanaga T, Cappuccini F, Jeffes EWB, Jakowatz JG. Lymphotoxin, Macrophage Toxins, Tumor Necrosis Factor and Cachectin in Tumor Necrosis Factor: Structure-Function Relationship and clinical Application. Basel, Karger, 1992:25-33. ***[International Conference on Cytokines and Tumor Necrosis Factor, Japan, 1991.]***
3. Jakowatz JG, et al: Placement of Indwelling Venous Access Systems in Vascular Access Surgery, 3rd Edition (Mosby Year Book, Inc., Publishers). 1996.
4. Jakowatz JG, et al: Indications, Devices and Techniques for Chronic Venous Access Devices Vascular Access: Principles and Practice, 4th Edition. (Mosby Year Book, Inc., Publishers).2002.
5. Jakowatz JG, Contributing Author: Cancer Prevention and Early Detection in Women, Manetta A. – Elsvier Mosby, October 2003.
6. Jakowatz JG, Contributing Author: Proecdures in Reconstructive Plastic Surgery, Elsvier, November 2008
ABSTRACTS
1. Jakowatz JG, Gan K, Ulich TR, Wile AG. Monoclonal antibodies and human pancreatic cancer. Proc Amer Soc Clin Oncology, Vol 6, abstract #925 p 235, May, 1987.
2. Jakowatz JG, Gan K, Ulich TR, Wile AG. Preneoplastic antigenic expression in non-neoplastic pancreatic tissue of pancreatic carcinoma and pancreatitis. Proceedings of the International Academy of Pathology Annual Meeting, March 1987, Boston, Massachusetts
3. Carson WE*, Jakowatz JG, Diffenbach, K*,et al. Intra-arterial TNF-alpha as treatment for regionally confined experimental extremity tumors in rats. 2nd International Conference on Tumor Necrosis Factor and Related Cytokines, No. WA 007, p 5, January 1989.
*Surgical residents under Dr. Jakowatz's direction.
4. Yamamoto RS, Beamer Y, Jacques D, Jeffes EWB, Jakowatz JG, Coss J, Granger, GA. Studies on longterm cultured human LAK cells from normal donors and patients with recurrent glioma. Growth characteristics, cytolytic activity and phenotype. FASEB Journal 3(3):827, abstract no. 3490, February 1989.
5. Jakowatz JG, Snyder, L*, Ginn, G*, et al. Effect of route and schedule of cisplatin administration. Proc Amer Soc Clin Oncology, Vol 8, p 66, March 1989.
*Surgical resident under Dr. Jakowatz's direction.
6. Carson WE*, Jakowatz JG, Diffenbach K*, Lucci J, Jeffes EWB, Yamamoto R, and Granger G. Intra-arterial TNF-alpha as treatment for regionally confined experimental extremity tumors in rats. Program and Abstracts of the 1989 Society for Biological Therapy Annual Meeting, abstract # 69, p 20, Boston, MA, November, 1989.
*Surgical residents under Dr. Jakowatz's direction.
7. Jeffes EWB, Yamamoto R, Beamer Y, Silberman R, Jacques D, Jakowatz JG, Gupta S, Vayuvegula B, and Granger G. Mitogen stimulated, IL-2 activated (MAK) lymphocyte therapy of recurrent high grade glioma patients. Program and Abstracts of the 1989 Society for Biological Therapy Annual Meeting, abstract # 68, p 20, Boston, MA, November, 1989.
8. Jakowatz JG, Carson, WE*, Sentovich S*, Dulkanchainum S, and Granger GA. Intra-arterial TNF for regionally confined extremity tumors in rats. Proc Amer Soc Clin Oncology, Vol 9, abstract # 321, p 83, May 1990.
*Surgical residents under Dr. Jakowatz's direction.
9. Liu S*, Jakowatz JG, Ceraldi C*, Sentovich S*, and Granger GA. Treatment of experimental brain gliomas with intracarotid tumor necrosis factor-alpha infusion. Proc Amer Assn Cancer Res, Vol 31, abstract # 1757, p 296, May 1990.
*Surgical residents under Dr. Jakowatz's direction.
10. Liu SK*, Jakowatz JG, Granger GA, Dett CA, Lopez F, Camacho C, Carson WE, and Sentovich S*. Immunotherapy of Brain Gliomas II. Efficacy of Intracarotid TNF and Intracarotid Lymphotoxin Compared in a Syngeneic Rat Model. Accepted for publication, Proceedings of the 3rd International Conference on Tumor Necrosis Factor and Related Cytokines, Sept., 1990.
11. Jeffes E, Yamamoto R, Beamer Y, Silberman R, Jacques D, Jakowatz J. Immunotherapy of human glioma II: Mitogen Stimulated IL-2 activated killer (MAK) lymphocyte therapy of recurrent high grade gliomas. Accepted for publication, Congress of Neurological Surgeons Annual Meeting, October 1990.
12. Sentovich S*, Jakowatz J, Ceraldi C*, Carson W*, Dett C, Granger G, and Liu S. Immunotherapy of brain cancer gliomas I: Efficacy of intracarotid TNF in Wistar rats. Submitted for publication, Congress of Neurological Surgeons Annual Meeting, October, 1990.
13. White JI, Gardner VO, Thalgott JS, Jakowatz JG, Palafox B, Hiroyuki T. Anterior Lumbar Fusion Using Allograft Femoral Shaft Bone: Preliminary Results. Accepted, Fifth International Conference on Lumbar Fusion and Stabilization, abstract #081, July 1991.
14. Sarfeh IJ and Jakowatz JG. Surgical Treatment of Enteric "Bud" Fistulae in Contaminated Wounds: A Riskless Extraperitoneal Method Using Split Thickness Skin Grafts. Accepted So. California Chapter of the American College of Surgeons, September 1991.
15. Meyskens FL Jr., Yamanishi DT, Jakowatz J, Goodman M. Abnormalities of Protein Kinase C (PKC)-B and Retinoic Acid Receptor (RAR)-B Expression During Human Melanocyte Progression to Melanoma. Accepted for presentation at the Third International Conference on Melanoma to be held in Venice, Italy 3-31-93.
16. Gordon IL, Jakowatz JG, Wuerker RB, and Willis, L. Detection of Colorectal Cancer Cells in Lavage Induced Stool. Submitted to the Society for Surgery of the Alimentary Tract New Orleans, May 1994.
17. Gordon IL, Ruth GD, Abai Y, Jakowatz JG, and Willis L. Increased Exfoliation of Gut Mucosal Cells Induced by Chenodeoxycholic Acid. Submitted to the Society for Surgery of the Alimentary Tract, New Orleans, May 1994.
18. Lugo S, Schechter A, Butler J, Jakowatz JG, and Gordon I. Automatic Minimally Invasive Morcellation System Allows Adequate Histologic Interpretation of Excised Tissue. The Southwestern Surgical Congress, April, 1994.
19. Regional Differences in the use of Sentinel Lymph Node Biopsy for Melanoma: A Potential Quality Measure. Karen Lane, MD, Ashley Kempf, BS, Cheryl Magno, MPH, John Lane, MD, John Butler, MD, David Hsiang, MD, Shelly Greenfield, MD, James Jakowatz, MD. Am Surg. 2008 Oct;74(10):981-4.
Professional Societies
Society for Academic Surgery
American Society of Clinical Oncology
Southwest Oncology Group Melanoma Committee
Melanoma Care Coalition
American Association for Cancer Research
Other Experience
Instructor in Surgery
Rush Medical College 1981—1983
Rush Medical College 1981—1983
Adjunct Attending Surgeon
Rush-Presbyterian; St. Luke's Medical 1982—1983
Rush-Presbyterian; St. Luke's Medical 1982—1983
Administrative Chief Resident, General Surgery
Rush-Presbyterian; St. Luke's Medical Center 1982—1983
Rush-Presbyterian; St. Luke's Medical Center 1982—1983
Assistant Professor In Residence
University of California, Irvine 1985—1992
University of California, Irvine 1985—1992
Associate Professor In Residence
University of California, Irvine 1992—2006
University of California, Irvine 1992—2006
Surgical Oncologist
Veterans Administration Medical Center, Long Beach, 1985—Pres
Veterans Administration Medical Center, Long Beach, 1985—Pres
Felllow, Surgical Oncology
City of Hope National Medical Center 1983—1985
City of Hope National Medical Center 1983—1985
Link to this profile
https://faculty.uci.edu/profile/?facultyId=2872
https://faculty.uci.edu/profile/?facultyId=2872
Last updated
07/13/2009
07/13/2009